clinical trial

AbbVie reports Phase 1 data for obesity treatment ABBV-295, showing 7.75%-9.79% weight loss. Stock declined despite positive results amid broader market pressure.

Anixa Biosciences secures patent protection in South Korea for breast cancer vaccine technology, advancing its IP portfolio as Phase 1 trial shows 74% immune response rate.

Editas Medicine reported Q4 2025 net loss of $5.6M, down 88% YoY. Lead CRISPR therapy EDIT-401 shows >90% LDL-C reduction; IND submission expected mid-2026.

Pfizer wins NMPA approval for weight-loss drug ecnoglutide in China, achieving 15.4% average weight loss in trials, intensifying competition as Novo Nordisk's Wegovy faces patent expiry.

Novo Nordisk's Kagrama showed weaker weight-loss results than Eli Lilly's Zepbound in 84-week trial, pressuring obesity growth forecasts.

Theravance Biopharma shares plummet 27% after ampreloxetine fails Phase 3 trial; company cuts workforce 50% and reduces expenses 60%.

EMA committee endorses mavorixafor (XOLREMDI) for WHIM syndrome treatment, marking first approved therapy in Europe. Final Commission approval expected Q2 2026.

Anteris secures $320M funding to advance DurAVR heart valve through global trials, with FDA approval and increased clinical development spending.

ImmunityBio completed Phase 3 cancer trial enrollment ahead of schedule with strong 85% response rates. Anktiva sales surged 750% year-over-year, hitting $38.29M in revenue.

Soligenix wins EMA orphan drug designation backing for SGX945 treating Behçet's Disease, following positive Phase 2a results and prior FDA support.

TScan completes Phase 1 trial enrollment and receives FDA clearance for two allogeneic cell therapy candidates, advancing its pipeline toward pivotal studies in 2026.

Tecovirimat showed no clinical benefit over placebo in treating mpox, with 79% vs 81% achieving resolution by day 29 in a major trial.

Arcutis reported 2025 revenue of $372.1M (123% growth) and raised 2026 guidance to $480-495M, driven by strong ZORYVE adoption and positive clinical data.

BVF Partners invests $52M in Disc Medicine despite FDA setbacks, betting on Phase 3 trial data and strong cash reserves through 2029.

Novo Nordisk cuts GLP-1 drug prices 50% to $675/month starting 2027 amid clinical setbacks and competitive pressure from rivals like Eli Lilly.

Artiva Biotherapeutics appoints veteran pharma executive Thad Huston as CFO with 30+ years experience, ahead of key FDA feedback and clinical data milestones.

Clene outlines 2026 regulatory milestones for ALS drug CNM-Au8, including FDA meeting, NDA submission, and Phase 3 trial, backed by $28 million funding.

Novo Nordisk's obesity drug UBT251 achieved 19.7% weight loss in Phase 2 trials for Chinese patients, offsetting recent setbacks from a failed competitor drug trial.

Bristol-Myers Squibb's Reblozyl achieved positive Phase 2 results for Alpha-Thalassemia, showing improved hemoglobin levels and reduced transfusion needs in patients.

REGENXBIO faces class action lawsuit alleging executives made false statements about RGX-111 gene therapy's efficacy and safety, seeking shareholder damages.